GUSTO V: Combination drug treatment of acute myocardial infarction

Arman T. Askari, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

A. Michael Lincoff, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: A. Michael Lincoff, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail lincofa@ccf.org

Dr. Lincoff has indicated that he has received grant/research support from the Centocor and Lilly corporations.

This paper discusses treatments that are not approved by the US Food and Drug Administration for the use under discussion.

Arman T. Askari, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

A. Michael Lincoff, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: A. Michael Lincoff, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail lincofa@ccf.org

Dr. Lincoff has indicated that he has received grant/research support from the Centocor and Lilly corporations.

This paper discusses treatments that are not approved by the US Food and Drug Administration for the use under discussion.

Arman T. Askari, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

A. Michael Lincoff, MD
Department of Cardiovascular Medicine, The Cleveland Clinic

Address: A. Michael Lincoff, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail lincofa@ccf.org

Dr. Lincoff has indicated that he has received grant/research support from the Centocor and Lilly corporations.

This paper discusses treatments that are not approved by the US Food and Drug Administration for the use under discussion.